Click Here to return To Results

 

Copolymer 1 Reduces Relapse Rate & Improves Disability in Relapsing-Remitting MS:Multictr Trial Neurol 45:1268-1276, Johnson,K.P.,et al, 1995 See this aricle in Pubmed Article Abstract We studied copolumer 1(Copaxone)in a multicenter(11-university)phase III trial of patients with relapsing-remitting multiple sclerosis(MS).Two hundred fifty-one patients were randomized to receive copolymer 1(n=125)or placebo(n=126)at a dosage of 20 mg by daily subcutaneous injection for 2 years.The primary end point was a difference in the MS relapse rate.The treatment was well tolerated.The most common adverse experience was an injection-site reaction.Rarely,a transient self-limited systemic reaction followed the injection in 15.2%of those receiving copolymer 1 and 3.2%of those receiving placebo.This reaction was characterized by flushing or chest tightness with palpitations,anxiety,or dyspnea and commonly lasted for 30 seconds to 30 minutes.This rigorous study confirmed the findings of a previous pilot trial and demonstrated that copolymer 1 treatment can significantly and beneficially alter the course of relapsing-remitting MS in a well-tolerated fashion.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction cop 1 interferon multiple sclerosis multiple sclerosis,relapsing multiple sclerosis,treatment of treatment of neurologic disorder

Click Here to return To Results